IntodnaS.A.
Research and experimental development in natural sciences and engineering
Overview
Intodna offers DNA damage detection and analysis of DNA repair biology using the STRIDE® platform. The company provides single-cell resolution and AI-driven data analysis. It serves pharmaceutical companies, biotechs, and research laboratories.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
intoDNA to Present Two Poster Presentations at the 2026 AACR Annual Meeting
– intoDNA to Present Two Poster Presentations at the 2026 AACR Annual Meeting –
intoDNA Forms Strategic Advisory Board with Leading Diagnostics and Precision Oncology Experts
– New board to accelerate the STRIDE® platform, revolutionizing DNA damage and repair diagnostics for precision oncology –
intoDNA Honored with the 2025 Supplier Recognition Award by Scientist.com
We are pleased to share that intoDNA has been honored with the 2025 Supplier Recognition Award by Scientist.com, a leading global R&D sourcing platform.
intoDNA Expands Leadership Team with Appointment of Maggie Rougier-Chapman as Chief Business Officer
– Appointment initiates U.S. expansion as STRIDE® scales biopharma services and progresses toward diagnostic readiness –
intoDNA’s STRIDE™ named 2025 “Overall Genomics Innovation of the Year” by BioTech Breakthrough
We’re thrilled to announce that intoDNA’s STRIDE™ Platform has been recognized as “Overall Genomics Innovation of the Year” by BioTech Breakthrough. The BioTech Breakthrough Awards aim to recognize the world’s top companies and solutions driving innovation across the life sciences and biotechnology sectors.
Industry
Bank accounts
Registered as a VAT taxpayer on 2017-12-22. Active
68 1750 0012 0000 0000 3853 3584- 67 1750 0012 0000 0000 4118 7328
- 41 1750 0012 0000 0000 4001 4969
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
10 public aid cases recorded, with a total value of $2,347,134.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 27, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $306.0K$306,028 | Marszałek Województwa Małopolskiego | |
| Mar 27, 2025 | Regional investment aid | $258.1K$258,112 | Marszałek Województwa Małopolskiego | |
| Jun 13, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $8,018$8,018 | Prezes Banku Gospodarstwa Krajowego |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-12-01 | Opracowanie i wdrożenie nowej metody do bezpośredniej detekcji i pomiaru stresu replikacyjnego w komórkach i tkankach ludzkich | $1.6M$1,559,662 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2024-09-01 | Inwestycja w rozbudowę infrastruktury laboratoryjnej INTODNA S.A w celu realizacji prac B+R, zmierzających do opracowania nowej technologii diagnostycznej dedykowanej identyfikacji i pomiarowi zjawisk występujących podczas replikacji DNA | $562.9K$562,867 | Fundusze Europejskie dla Małopolski 2021-2027 | |
| 2021-02-18 | Wdrożenie prac badawczo rozwojowych w celu rozpoczęcia świadczenia usługi wsparcia badań klinicznych nowych terapii onkologicznych. | $207.1K$207,103 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
Each member of the management board acting independently is authorised to submit declarations of will concerning property rights and obligations and to sign on behalf of the company, provided that joint action by two members of the management board acting jointly is required to incur obligations or dispose of a right in an amount equal to or exceeding PLN 250,000.00 (two hundred and fifty thousand zlotys).
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Magdalena Maria Kordon-Kiszala (39)  | Shareholder of a joint-stock company, 35.0% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Scope FluidicsS.A. | $3,082,936.61 | scopefluidics.com | ||
| Centrum Badań i Rozwoju Technologii dla PrzemysłuS.A. | $2,559,521.35 | cbrtp.pl | ||
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| SkinlabP.S.A. | $1,797,229.06 | skinlab.pl | ||
| Eurxsp. z o.o. | $1,644,555.44 | eurx.com.pl | ||
| Aslab ScienceP.S.A. | $1,504,132.17 | aslabsci.com | ||
| BiokineticaS.A. | $1,292,838.89 | biokinetica.com | ||
| COS LabP.S.A. | $1,028,123.83 | coslab.pl | ||
| Bulletprovesp. z o.o. | $867,545.53 | bulletprove.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-05-05 | Share capital change (107,431.35 PLN → 108,130.10 PLN) | |
| 2025-09-05 | Share capital change (100,000.00 PLN → 107,431.35 PLN) | |
| 2020-12-31 | Entered in the register |
FAQ
Last updated: 2026-07-15